About the Company
9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NMTR News
9 Meters Biopharma Inc. (NMTRQ)
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome ...
North American Morning Briefing: Tech in Focus on -2-
Powered by Kantar Media and Dow Jones. Expected Earnings for Monday 9 Meters Biopharma Inc (NMTRQ) is expected to report for 4Q. Ampco-Pittsburgh Corp (AP) is expected to report for 4Q.
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically ...
Biopharma M&A more than doubled in Q1 compared to the year prior: report
The number of biopharma M&A deals more than doubled in the first quarter of 2024 ... stock prices are up 29%. Vertex pays ...
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that ...
First Wave BioPharma’s stock more than doubles after deal to sell its IBD treatment
Shares of First Wave BioPharma Inc. rocketed 123% in premarket trading ... while the iShares Biotechnology ETF has gained 9.7% and the S&P 500 has rallied 11.7%.
Benitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a ... from the first ...
Aytu BioPharma, Inc. Common Stock (AYTU)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
NEW YORK, April 9, 2024 /PRNewswire/ -- Monteverde & Associates ... Building in New York City and is investigating ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed merger to Oruka ...
Loading the latest forecasts...